Johnson & Johnson Stock Performance - Johnson & Johnson (JNJ) started 2024 at the same price as it started 2020, indicating no price appreciation over four years [1] - Despite a decent dividend, the lack of price appreciation makes the stock less attractive [1] Analyst Background - The analyst focuses on long-term investing through low-risk ETFs and CEFs [1] - The analyst has nearly ten years of experience trading stocks and currencies [1] - The analyst manages a family fund and invests in real estate [1] Disclosure and Disclaimer - The analyst has no stock, option, or derivative positions in the mentioned companies and no plans to initiate any within the next 72 hours [2] - The article expresses the analyst's own opinions and is not compensated by any company mentioned [2] - Seeking Alpha's disclosure states that past performance is no guarantee of future results and no investment advice is being given [3]

Stock Performance - Johnson & Johnson (JNJ) closed at $146 18, marking a +1 75% increase from the previous day, outperforming the S&P 500's daily loss of 1 11% [1] - Over the past month, JNJ shares lost 3 97%, outperforming the Medical sector's loss of 6 22% but lagging behind the S&P 500's loss of 1 7% [1] Earnings and Revenue Forecast - JNJ's upcoming earnings report is set for January 22, 2025, with an expected EPS of $2, indicating a 12 66% decline compared to the same quarter last year [2] - Revenue is anticipated to be $22 54 billion, reflecting a 5 37% increase from the same quarter last year [2] Analyst Revisions and Zacks Rank - Recent revisions to analyst forecasts for JNJ reflect changing near-term business trends, with positive revisions indicating optimism about the company's profitability [3] - The Zacks Consensus EPS estimate has increased by 0 03% over the last 30 days, and JNJ currently holds a Zacks Rank of 2 (Buy) [5] - The Zacks Rank system has a strong track record, with 1 stocks generating an average annual return of +25% since 1988 [5] Valuation Metrics - JNJ's Forward P/E ratio is 13 62, representing a premium compared to the industry average of 12 34 [6] - The company's PEG ratio is 2 33, higher than the Large Cap Pharmaceuticals industry average of 1 26, indicating a higher valuation relative to expected earnings growth [7] Industry Overview - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 191, placing it in the bottom 24% of all industries [8] - Industries in the top 50% of the Zacks Industry Rank outperform the bottom half by a factor of 2 to 1 [8]

Johnson & Johnson (NYSE: JNJ ) is a one big enigma right now. And I like it. I’ve owned it since May and it has been a experience not unlike many I have had with other high quality dividend stocks. It isI'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden YARP Portfolio, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income investing. I've been charting investments since the 1980s, ...

Median overall survival improvement expected to exceed one yearFirst and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancerRARITAN, N.J., Jan. 7, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) as a first-line therapy for p ...

J&J's Legal and Financial Challenges - J&J faces over 62,000 lawsuits related to its talc-based products, primarily baby powders, alleging asbestos contamination causing ovarian cancer [9] - The company failed twice in bankruptcy attempts to resolve talc lawsuits and proposed a $6.5 billion settlement over 25 years to resolve 99.75% of pending cases [2] - J&J's stock has underperformed the industry, falling 7.5% year-to-date compared to the industry's 3.1% growth [13] Patent Expiration and Market Impact - J&J's blockbuster drug Stelara, which generated $8.0 billion in sales in the first nine months of 2024, faces patent expiration in 2025 [3] - Biosimilars for Stelara are expected to launch in the US in January 2025, potentially eroding sales and profits [3] MedTech Segment Performance - J&J's MedTech segment faces headwinds in Asia Pacific, particularly in China, due to the volume-based procurement (VBP) program and anti-corruption campaign [11] - The company expects operational sales in the MedTech segment to grow 5% in 2024, near the lower end of its long-term target of 5%-7% [11] Innovative Medicine Unit Growth - J&J's Innovative Medicine unit is performing above market levels, with sales growth of 6.8% in 2022, 9% in 2023, and 5.6% in the first nine months of 2024 [12] - The company expects 10 new Innovative Medicine products, including cancer drugs Talvey and Tecvayli, to deliver peak non-risk-adjusted operational sales of $5 billion [5] Valuation and Stock Performance - J&J's stock is trading below its 200-day and 50-day moving averages and is cheaper than peers like Eli Lilly and Novo Nordisk [14] - The stock closed at $145.05, close to its 52-week low of $142.75, and has lost more than 10% in the past three months [19] Future Outlook and Strategic Moves - J&J expects positive growth in the Innovative Medicine segment in 2025 despite Stelara's patent expiration, with growth driven by key products like Darzalex and Tremfya [28] - The company has completed acquisitions in MedTech and Innovative Medicine, boosting its pipeline and expecting operational sales growth at the upper end of its 5-7% long-term target [27][28] Industry and Sector Trends - The drug and biotech sector experienced a downturn in the second half of the year due to disappointing Q3 sales, guidance cuts, pipeline setbacks, and political appointments [8] - J&J's stock underperformance is part of a broader trend affecting large drugmakers, influenced by sector-wide challenges [8]

Technical Analysis - JNJ stock's eight-day simple moving average of $144 97 is slightly below its current price, indicating a rare bullish signal [1] - JNJ stock has entered a bearish technical pattern known as the Death Cross, where the 50-day moving average falls below the 200-day moving average [3][6] - JNJ stock is currently priced at $145 58, below critical moving averages: 20-day ($144 97), 50-day ($154 24), and 200-day ($154 66), suggesting a firmly bearish trend [7] - The MACD is negative 2 72 and the Relative Strength Index is 36 84, further indicating a lack of confidence in the technical setup [7] Strategic Moves - The company is strategically focusing on differentiated mechanisms of action in dermatology [8] - Acquisitions in 2024 have bolstered the dermatology pipeline, emphasizing innovative treatments for atopic dermatitis (AD) and other immune-mediated conditions [8] - A licensing deal with Kaken Pharmaceutical for KP-723, a promising candidate targeting atopic dermatitis, is in place with plans to launch a phase I study in 2025 [11] Dividend and Financial Health - The company has ample liquidity, low leverage, and robust free cash flow, ensuring solid dividend sustainability despite bearish technical indicators [9] - Johnson & Johnson is a dividend aristocrat with over 60 years of consistent payouts, providing a safety net for investors [12] Long-Term Outlook - Despite the Death Cross casting a shadow over the short-term outlook, the company's commitment to growth, innovation, and reliable dividends underscores its long-term appeal [13] - The company is looking to tackle eczema and diversify its portfolio, indicating that the stock may be down but far from out [14]

Core Viewpoint - Johnson & Johnson (JNJ) has entered into an exclusive global licensing agreement with Kaken Pharmaceutical to develop and commercialize Kaken's STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD) [1][2]. Group 1: Licensing Agreement Details - The licensing deal grants JNJ global rights to Kaken's lead candidate, KP-723, which is being developed as an oral pill for AD, expected to enhance patient compliance [1][4]. - Kaken retains commercialization rights for KP-723 in Japan, allowing JNJ to enter a copromotion agreement with Kaken [5]. - In consideration of the licensing agreement, Kaken is eligible for an equity investment from JNJ [5]. Group 2: Strategic Focus and Pipeline - JNJ is focusing on targeting disease-specific pathways and has added other development candidates to its dermatology pipeline, emphasizing differentiated mechanisms to treat AD [6]. - The STAT6 program is seen as a promising area of research, addressing a significant unmet medical need as most AD patients do not achieve remission with current treatments [8]. Group 3: Market Context and Performance - In the past three months, JNJ shares have declined by 10.2%, compared to a 13.8% decline in the industry [3]. - AD affects over 9.6 million children and 16.5 million adults in the U.S., significantly impacting their quality of life [9].

Dividend-paying stocks are the gift that keeps on giving. They pay you a recurring stream of passive income that you can use to make new investments or cover some of your expenses. The best dividend stocks will send you more money each year by increasing their payments. Anybody can gift oneself with a multiyear supply of passive income by purchasing shares of a high-quality dividend-paying company. Three great ones to consider buying are Coca-Cola (KO -0.27%), Johnson & Johnson (JNJ 0.55%), and NextEra Ener ...

Company Performance - Johnson & Johnson (JNJ) ended the latest trading session at $145.27, reflecting a +0.55% adjustment from the previous day's close, which lagged behind the S&P 500's gain of 0.73% [1] - Over the past month, JNJ shares have decreased by 6.9%, underperforming the Medical sector's loss of 3.8% and the S&P 500's gain of 0.34% [1] Upcoming Earnings - Johnson & Johnson is scheduled to release its earnings on January 22, 2025, with an expected EPS of $2, indicating a 12.66% decline from the same quarter last year [2] - The Zacks Consensus Estimate projects net sales of $22.54 billion, which is a 5.37% increase from the year-ago period [2] Full Year Projections - For the full year, the Zacks Consensus Estimates forecast earnings of $9.94 per share and revenue of $88.84 billion, showing changes of +0.2% and -4.49% respectively from the previous year [3] Analyst Estimates - Recent modifications to analyst estimates for Johnson & Johnson are crucial as they reflect near-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, provides actionable ratings for investors [5] Zacks Rank and Valuation - Johnson & Johnson currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having increased by 0.04% over the last 30 days [6] - The company is trading at a Forward P/E ratio of 14.54, which is a premium compared to the industry average Forward P/E of 13.74 [7] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 131, placing it in the bottom 48% of all industries [8] - Johnson & Johnson has a PEG ratio of 2.49, compared to the industry average PEG ratio of 1.44 [10]

Group 1 - The article discusses the addition of Johnson & Johnson (NYSE: JNJ) stock to a portfolio to rebalance it after significant rallies in growth stocks, indicating a shift towards defensive plays [1] - The author emphasizes the importance of balancing a portfolio with low-volatility dividend-paying stocks alongside growth opportunities, reflecting a well-rounded investment strategy [1] - The analysis focuses on high-quality companies with reasonable valuations rather than seeking deep discounts, highlighting the potential risks associated with excessively cheap stocks [1] Group 2 - The author has a beneficial long position in JNJ shares, indicating confidence in the stock's performance [2] - The article expresses personal opinions and does not involve compensation from any company mentioned, ensuring an unbiased perspective [2] - The content does not provide specific investment recommendations, emphasizing that past performance is not indicative of future results [3]